# Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease

> **NCT04805099** · — · COMPLETED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 126 (actual)

## Conditions studied

- Autoimmune Diseases
- Checkpoint Inhibitor
- Immunotherapy

## Interventions

- **DRUG:** Checkpoint inhibitor

## Key facts

- **NCT ID:** NCT04805099
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-01
- **Primary completion:** 2021-01-30
- **Final completion:** 2021-02-28
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04805099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04805099, "Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04805099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*